KALA BIO, Inc. — Director's Dealing 2020

Jun 30, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2019-08-19

Reporting Person: Rosen Howard B (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-08-19	Common Stock	M	2880	$0.68	Acquired	2880	Direct
2019-08-19	Common Stock	M	1944	$0.47	Acquired	4824	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-08-19	Stock Option (right to buy)	$0.68	M	2880	Disposed	2023-05-10	Common Stock (2880)	Direct
2019-08-19	Stock Option (right to buy)	$0.47	M	1944	Disposed	2021-06-16	Common Stock (1944)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8240	Indirect

Footnotes

F1: These shares arc owned directly by the Rosen/Doherty Rcvocablc Trust Dated 6/11/01 (the 'Trust"), and indirectly by Mr. Rosen as co-trustee of the Trust. Prior reports filed on July 19, 2017 and Junc 3, 2019 incorrectly reported that these shares were directly hcld by Mr. Rosen.

F2: The option was fully vested.

F3: The option was fully vested.